The role of tissue factor and tissue factor pathway inhibitor in blood coagulation and in thrombotic complications;Rola czynnika tkankowego i jego inhibitora w procesie krzepniȩcia krwi oraz w powikłaniach zakrzepowych

Kardiologia Polska

Volumn 68, Issue 10, 2010, Pages 1158-1162

  Kotschy, Maria ^a   Kotschy, Daniel ^a   Witkiewicz, Wojciech ^a  

^a Department of Radiology   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT RESPIRATORY DISTRESS SYNDROME; ANGIOGENESIS; BLOOD CLOTTING; CANCER PATIENT; ENDOTHELIUM CELL; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; PATHOGENESIS; REVIEW; THROMBOPHILIA; THROMBOSIS;

EID: 78149319486     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Broze GJ, Leykam JE, Schwartz BD, Miletich JP. Purification of human brain tissue factor. J Biol Chem, 1985; 260: 10917-10920.
2. Mackman N, Morrissey JH, Fowler B, Edgington TS. Complete sequence of the human tissue factor gen a highly regulated cellular receptor that iniciates the coagulation protease cascade. Biochemistry, 1989; 28: 1755-1762.
3. Nemerson Y, Luther T, Kotzchy M, Müller M. Tissue factor: then and now. Thromb Haemost, 1995; 74: 180-184.
4. Naumnik B, Małyszko J, Myœliwiec M. Rola czynnika tkankowego i jego inhibitora w hemostazie. Przegl Lek, 1998; 55: 68-73.
5. Gouin-Thibault I, Achkar A, Samama MM. The thrombophilic state in cancer patients. Acta Haematol, 2001; 106: 33-42.
6. Müller Y, Ultsch M, Kelly RF, de Vos AM. Structure of the extracellular domain of human tissue factor: location of the factor VIIa binding site. Biochemistry, 1994; 33: 10864-10867. (Pubitemid 24296338)
7. Steffel J, Thomas F, Lüscher MD, Felix C, Tanner MD. Tissue factor in cardiovascular diseases. Circulation, 2006; 113: 722-731.
8. Carmeliet P, Mackman N, Moons L et al. Role of tissue factor in embrionic blood vessel development. Nature, 1996; 383: 73-75.
9. Giesen PL, Rauch U, Bohrmann B et al. Blood borne tissue factor, another view of thrombosis. Proc Natt Acad Sci USA, 1999; 96: 2311-2315.
10. Szotowski B, Antoniak S, Poller W et al. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Cir Res, 2005; 96: 1233-1239.
11. Parhami-Seren B, Butenas J, Krudysz-Amblo J, Mann KG. Immunologic quantitation of tissue factors. Thromb Haemost, 2006; 4: 1749-1755.
12. Uszyñski M, Żekanowska E, Uszyñski W, Kuczyñski J. Tissue factor (TF) and tissue pathway inhibitor (TFPI) in amniotic fluid and blood plasma, implication for the mechanism of amniotic fluid embolism. Eur J Obstet Gynecol Reprod Biol, 2001; 95: 163-166.
13. Felmelden DC, Spencer CG, Clung NA et al. Relation of thrombogenesis in systematic hypertension to angiogenesis and endothelial damage (dysfunction) a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Cardiol, 2003; 92: 400-405.
14. He M., He X., Xie Q, Chen F, He S. Angiotensin II induced the expression of tissue factor and its mechanisms in human monocytes. Thromb Res, 2005; 4: 33-36.
15. Lim HS, Blann AD, Lip GY. Soluble CD40 ligand, soluble P-selectin, interleukin 6 and tissue factor in diabetes mellitus, relationships to cardiovascular disease and risk factor intervention. Circulation, 2004; 109: 2524-2528.
16. Eto M, Kozai T, Cosentino F et al. Statin prevents tissue factor expression in human endothelials cells; role of Rho/Rho-kinase and akt pathway. Circulation, 2002; 105: 1756-1759. (Pubitemid 34408880)
17. Annex BH, Denning SM, Channon KM et al. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation, 1995; 91: 619-622.
18. Migdalski A, Kotschy M, Jawieñ A. Tissue factor, tissue pathway inhibitor and vascular endothelial growth factor in carotid atherosclerotic plaques. Eur J Vasc Endovasc Surg, 2005; 30: 41-47.
19. Molero L, Lopez-Farre A, Mateos-Caceres PJ et al. Effect of clopidogrel on the expression of inflammatory markers in rabbit ischemic coronary artery. Br J Pharmacol, 2005; 146: 419-424.
20. Seljeflot I, Hurten M, Arnesen H. Increased level of soluble tissue factor during longtherm treatment with warfarin patients after an acute myocardial infarction. Thromb Haemost, 2004; 2: 726-730.
21. Tutar E, Oscan M, Kilicap M et al. Elevated whole blood tissue factor procoagulant activity as a marker of restenosis after percutaneus transluminal coronary angioplasty and stent implantation. Circulation, 2003; 108: 1581-1584.
22. Crillo P, Galino P, Ragni M et al. Long-lasting antithrombotic effects of a single dose of human recombinant active site-blocked factor VII, insights into possible mechanism of action. Thromb Haemost, 2003; 1: 992-998.
23. Moons AH, Peters RJ, Bijsterveld NR et al. Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/ factor VIIa complex in patients undergoing elective coronary angioplasty. Am Coll Cardiovasc, 2003; 41: 2147-2153.
24. Broze GJ Jr., Miletich JP. Isolation of the tissue factor inhibitor produced by HepG2 hepatoma cells. Proc Natl Acad Sci USA, 1987; 84: 1886-1890.
25. Wun TC, Kretzmer KK, Girard TJ et al. Cloning and characterization of cDNA coding for the lipoprotein associated inhibitor shows that it consists of three tandem Kunitz type inhibitory domains. J Biol Chem, 1988; 263: 6001-6004.
26. Rucińska M, Gacko M, Skrzydlewski Z. Inhibitor zależnej od czynnika tkankowego drogi krzepniȩcia krwi (TFPI) i jego znaczenie w patologii. Post Hig Med Dośw, 1997; 51: 421-430.
27. Witt I. Tissue factor pathway inhibitor biochemistry molecular biology, physiology and pathophysiology. Haemostaseologie, 2002; 22: 30-35.
28. Girard TJ, Eddy R, Wesserschmidt RL et al. Structure of the human lipoprotein-associated coagulation inhibitor gene. Intro/ ex on gene organization and localization of the gene to chromosome 2. J Biol Chem, 1991; 263: 6001-6004.
29. Sayer MS, Cole VJ, Baker R, Staton JM. Polymorphismus in the tissue factor pathway inhibitor gene are not associated with ischemic stroke. Blood Coagul Fibrinolysis, 2007; 18: 703-708.
30. Gori AM, Pepe G, Attanasio M et al. Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration. Thromb Haemost, 1999; 81: 589-593.
31. Edstrom CS, Calhoun DA, Christiansen RD. Expression of tissue factor pathway inhibitor in human fetal and placental tissues. Early Hum Dev, 2000; 59: 77-84.
32. Caplice NM, Mueske CS, Kleppe LS, Simira RD. Presence of tissue factor inhibitor In human atherosclerotic plaques is associated with reduced tissue factor activity. Circulation, 1998; 98: 1051-1053.
33. Gosk-Bierska I, Wysokiñski W, Karnicki K, Adamiec R. Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischemia: preliminary study. Int Angiol, 2008; 27: 296-301.
34. Radziwon P, Bielawiec M, Kłoczko J et al. Tissue pathway inhibitor (TFPI) in patients with occlusive arterial diseases in consideration with risk factors and conservative treatment of the disease Acta Angiol, 2001; 7: 43-54.
35. Ameri H, Hyers TM, Tricomi S et al. Transcriptional expression of tissue pathway inhibitor (TFPI) in alveolar macrophages of patients with adult respiratory distress syndrome (ARDS). Blood, 1997; 78: 107.
36. Yamamuro M, Wada H, Kumeda K et al. Changes in plasma tissue factor pathway inhibitor levels during the clinical course of disseminated intravascular coagulation. Blood Coagul Fibrinolysis, 1998; 9: 491-497.
37. Iversen N, Lindahl AK, Abildgaard U. Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation. Br J Haematol, 1998; 102: 889-895. (Pubitemid 28410516)
38. Leurs PB, van Oerle R, Wolffenbutel BH. Increased tissue factor pathway inhibitor TFPI and coagulation in patients with insulin dependent diabetes mellitus. Thromb Haemost, 1997; 77: 472-476.
39. Falciani M, Gori AM, Fedi S et al. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischemic heart disease patients. Thromb Haemost, 1998; 78: 495-499.
40. Harris GM, Stendt CL, Vollenhoven BJ et al. Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives. Am J Hematol, 1999; 60: 175-180.
41. Eling M, Stephens AC, Oragui EE et al. Tissue factor pathway inhibitor (TFPI) levels in the plasma and urine of children with meningococcal disease. Thromb Haemost, 2001; 85: 240-244.
42. Ariens RA, Moia M, Rivolta E et al. High levels of tissue factor pathway inhibitor in patients with nephrotic proteinuria. Thromb Haemost, 1999; 82: 1020-1023. (Pubitemid 29419712)
43. Naumnik B, Borawski J, Chyczewski L et al. Tissue factor and its inhibitor in human non-crescentic glomerulonephritis-immunostaining vs plasma and urinary levels. Nephrol Dial Transplant, 2006; 21: 3450-3457.
44. Bajaj MS, Bajaj SP. Tissue factor pathway inhibitor potential therapeutic applications. Thromb Haemost, 1997; 78: 471-477. (Pubitemid 27289287)